Therapeutic Area: Haematological

A Study of Co-formulated Favezelimab/Pembrolizumab Versus Doctor’s Choice Chemotherapy in PD-1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma

By

The purpose of this study is to compare efficacy of co-formulated favezelimab/pembrolizumab (MK-4280A) with doctor’s choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory, relapsed or refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of co-formulated favezelimab/pembrolizumab. The primary study hypotheses are that co-formulated favezelimab/pembrolizumab is superior to doctor’s … Continued

Efficacy and Safety of Nemtabrutinib in Participants With Haematological Malignancies

By

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with haematological malignancies of chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM).